Skip to content

Advertisement

  • Case Report
  • Open Access

Bevacizumab is associated with delayed anastomotic leak after low anterior resection with preoperative radiotherapy for rectal cancer: a case report

  • 1,
  • 1Email authorView ORCID ID profile,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1,
  • 2 and
  • 1
Surgical Case Reports20195:14

https://doi.org/10.1186/s40792-019-0573-1

  • Received: 28 November 2018
  • Accepted: 21 January 2019
  • Published:

Abstract

Background

Bevacizumab is an anti-angiogenesis agent used to treat patients with metastatic colorectal cancer and is associated with a variety of complications. We present a patient with rectal cancer who developed a delayed anastomotic leak more than 5 years after undergoing low anterior resection.

Case report

A 78-year-old man with hematochezia was diagnosed with two synchronous rectal cancers 7 years prior to presentation. Preoperative chemo-radiotherapy was given followed by a very low anterior resection. During follow-up, multiple lymph node metastases developed, which were treated with chemotherapy. First-line chemotherapy, capecitabine, oxizaliplatin, and bevacizumab, was given over 3 years, and second-line chemotherapy, capecitabine, irinotecan, and bevacizumab, was administered over a 3-month period. After the last treatment, the patient presented with pneumaturia and fecaluria. Computed tomography scan revealed extraluminal air between the prostate and rectum, adjacent to the anastomotic site. Ulceration and fistula formation were observed on colonoscopy, and contrast radiography demonstrated a fistula at the anastomotic site. An anastomotic-urethral fistula was diagnosed and transverse colostomy was performed.

Conclusions

This patient highlights a rare late adverse event at the anastomotic site associated with bevacizumab treatment and preoperative chemo-radiotherapy. Signs and symptoms suggesting anastomotic complications should be thoroughly evaluated during bevacizumab treatment, even long after surgical resection.

Keywords

  • Rectal cancer
  • Bevacizumab
  • Chemo-radiotherapy
  • Delayed anastomotic leak

Background

Bevacizumab, a humanized monoclonal antibody that targets vascular endothelial growth factor (VEGF)-A, is an anti-angiogenesis agent used to treat patients with metastatic colorectal cancer (CRC) in combination with 5-fluorouracil (5-FU)-based chemotherapy as both first- and second-line treatment [1, 2]. Bevacizumab can lead to a variety of adverse events such as arterial thrombosis [3], hemorrhage [4], and gastrointestinal perforation [5]. In addition, bevacizumab treatment increases the risk of developing an anastomotic leak in patients with rectal cancer who underwent low anterior resection. Delayed anastomotic leak, especially more than 3 months after surgery, is rare. A small number of case reports have described this complication [611]. We present a patient with rectal cancer who developed a delayed anastomotic leak more than 5 years after undergoing low anterior resection who had received preoperative chemo-radiotherapy (CRT).

Case presentation

A 78-year-old man with hematochezia was diagnosed with two synchronous rectal cancers 7 years prior to presentation. One tumor was located at the rectosigmoid junction (stage T3N1M0, well-differentiated tubular adenocarcinoma), and the second was in the distal rectum, (stage T3N1M0, well-differentiated tubular adenocarcinoma). The patient had a 10-year history of diabetes mellitus and hypertension treated with medication. No family history of CRC was noted. Physical examination was unremarkable. Preoperative CRT followed by a very low anterior resection with diverting ileostomy was performed. Preoperative CRT included 5 days of 5-FU/leucovorin infusion followed by radiation therapy delivered using the four-field technique with photon radiation administered five times per week with a daily fraction of 1.8 Gy, for a total of 40 Gy. The final pathological diagnosis revealed that the rectosigmoid cancer was ypT3N1M0, and the lower rectal cancer was ypT0N0M0 (no residual cancer, pathological complete response). The postoperative course was uneventful and the ileostomy was reversed 8 months later, after completion of postoperative adjuvant chemotherapy, which included 6 months of oral 5-FU/leucovorin.

During follow-up, multiple lymph node metastases in the para-aortic and supraclavicular regions were found 20 months after resection and chemotherapy was given, including 14 days of oral capecitabine, 1 day of oxizaliplatin (CAPOX), and bevacizumab. Bevacizumab (7.5 mg/kg) was administered intravenously on day 1 for 1 cycle. CAPOX+bevacizumab was continued for 3 years for a total of 33 cycles of CAPOX (combined with 23 cycles of bevacizumab). Progression of lymph node metastases was noted and the chemotherapy regimen was changed. Second-line chemotherapy included 14 days of oral capecitabine, 1 day of irinotecan (XELIRI), and bevacizumab. Three cycles of XELIRI+bevacizumab (7.5 mg/kg) were continued over 3 months. One month after the last course of chemotherapy (5 years after resection), the patient presented with pneumaturia and fecaluria and described three previous episodes of hematochezia. The patient had no other symptoms associated with altered bowel habits. Laboratory tests demonstrated signs of mild inflammation (white blood cell count 11,200 μL, C-reactive protein 2.2 mg/dL). A small amount of extraluminal air between the prostate and rectum, adjacent to the anastomotic site, was observed on computed tomography (CT) scan (Fig. 1), which was not noted on the previous CT scans. Routine surveillance colonoscopy was not performed after the initial surgery as care was focused on management of multiple lymph node metastases. The latest colonoscopy revealed ulceration and fistula formation at the anastomotic site (Fig. 2). Contrast radiography was consistent with a fistula at the anastomotic site (Fig. 3). Only granulation tissue, including inflammatory changes, was seen in biopsies taken from the anastomotic site. Colonoscopy, contrast radiography, and cystoscopy demonstrated no recurrent tumor or obvious anastomotic-urethral fistula at the anastomosis, but an anastomotic-urethral fistula was suspected based on symptoms including pneumaturia and fecaluria. Transverse colostomy was performed and has not been reversed because of the continued need for chemotherapy. At this time, the patient has no symptoms associated with a leak and CT scan shows no air around the anastomotic site.
Fig. 1
Fig. 1

Computed tomography scan of the abdomen revealed a small amount of extraluminal air between the prostate and rectum, adjacent to the anastomotic site (white arrow)

Fig. 2
Fig. 2

Ulceration and fistula formation are observed at the site of the colonic anastomosis on colonoscopy

Fig. 3
Fig. 3

Fistula formation was observed at the anastomotic site after low anterior resection on contrast radiography. Arrow head and arrow indicate fistulae which go to the anterior and posterior side of the anastomosis, respectively. There was no anastomotic-urethral fistula seen on contrast enema

Discussion

The present patient developed a delayed anastomotic leak associated with bevacizumab treatment for metastatic rectal cancer, which presented more than 60 months after a very low anterior resection with primary anastomosis. Although multiple para-aortic lymph node metastases were observed, there was no recurrence of the tumor at the anastomotic site when the leak occurred. Previous treatment with preoperative CRT may be associated with this delayed anastomotic leak. This patient highlights a rare late adverse event at the anastomotic site associated with bevacizumab treatment and preoperative CRT.

Anastomotic leak is one of the most serious complications following colorectal surgery, and generally occurs within 30 days postoperatively. However, recent studies have reported that anastomotic leaks can also occur more than 30 days after surgery. Risk factors for early anastomotic leak following rectal surgery include a low site of anastomosis, male gender, and the presence of intraoperative difficulties, which may correlate with the degree of surgical difficulty [1214]. Delayed anastomotic leak does not seem to be associated with technical factors. The risk factors for delayed anastomotic leak include female gender, low anastomosis, preoperative CRT, and fistula formation [15, 16]. Of these risk factors for the development of delayed anastomotic leak, the present patient had a low anastomosis and preoperative CRT. Radiotherapy affects wound healing by inducing vascular injury, inhibiting angiogenesis and impairing fibroblasts [17]. Anastomosis creates a region of marginal vascularization, which may incur further ischemic damage by radiotherapy. Delayed anastomotic leak may occur regardless of bevacizumab administration.

Gastrointestinal perforation is a well-described complication of bevacizumab administration that has been reported in up to 2% of patients with CRC and can occur at any time during treatment [18]. The anastomosis is a well-known site for perforation. An intact primary tumor, concomitant use of non-steroidal anti-inflammatory drug, advanced age, and previous radiotherapy were found to be significant risk factors for the development of gastrointestinal perforation associated with bevacizumab treatment [19, 20]. Bevacizumab-related delayed anastomotic leak is extremely rare.

There have only been nine patients treated with bevacizumab in six reports of delayed anastomotic leak occurring more than 12 months postoperatively [611]. The clinical features of all 10 patients, including the present patient, are summarized in Table 1. All patients had rectal cancers and underwent preoperative CRT. The leaks occurred after beginning bevacizumab treatment, and 40% had a previous history of anastomotic leak. The median time to detecting the leak after the initial surgery was 30 months in the previously reported nine patients. We compared the duration of bevacizumab treatment between patients with a delayed leak occurring more or less than 30 months after primary anastomosis. The median duration of bevacizumab treatment in six patients with a greater than 30 month interval was longer (20 weeks) than the median in four patients with a less than 30 month interval (6 weeks). The interval between the last bevacizumab dose and leak was not different in the two groups. In the present patient, the leak occurred after 60 months, the longest reported interval following resection, and 3 years, the longest duration of bevacizumab treatment of the 10 patients reviewed. Long-term follow-up at the anastomotic site is needed for patients who receive bevacizumab treatment. Significant risk factors associated with the development of delayed anastomotic leak include a low anastomotic site, preoperative CRT, and bevacizumab treatment.
Table 1

Clinical features of ten patients with delayed anastomotic leak associated with bevacizumab treatment

Report

Age/gender1

Primary tumor

Preoperative radiation therapy

Previous history of anastomotic leak

Anastomotic complication

Interval between initial surgery and leak (months)

Duration of bevacizumab treatment

Interval between last bevacizumab dose and leak

Adenis et al. [9]

50/F

Rectum

Yes

Yes

Leak ileovaginal fistula

22

1 month (2 doses)

< 1 month

Ley et al. [7]

72/F

Rectum

Yes

No

Leak rectovaginal fistula

30

6 months

< 1 month

August et al. [6]

58/M

Rectum

Yes

Yes

Leak

26

6 weeks (3 doses)

Not described

August et al. [6]

74/F

Rectum

Yes

No

Leak

33

20 weeks

4 months

Bege et al. [8]

46/M

Rectum

Yes

Yes

Leak

52

Not described

1 week

Bege et al. [8]

54/M

Rectum

Yes

Yes

Leak

57

Not described

2 weeks

Bege et al. [8]

51/M

Rectum

Yes

No

Leak

21

Not described

2 weeks

Borzomati et al. [10]

68/M

Rectum

Yes

Yes

Leak

33

24 weeks

2 weeks

O’Hare et al. [11]

56/F

Rectum

Yes

No

Leak

17

6 weeks (3 doses)

1 month

Present patient

78/M

Rectum

Yes

No

Leak

60

3 years (26 doses)

1 month

1F female, M male

In the present patient, the delayed anastomotic leak was detected 3 cycles after beginning an irinotecan-based regimen. Irinotecan is also suspected to be associated with the development of delayed anastomotic leaks, but usually causes a range of toxicities including diarrhea and neutropenia, and the incidence of gastrointestinal perforation is much less than with bevacizumab-based treatment [5, 21, 22]. In addition, no previous report of delayed anastomotic leak due to irinotecan was identified. After creating the transverse colostomy for treatment of the leak, irinotecan plus anti EGF receptor drug has been given. There is no evidence of further leak. In consideration of previous reports, bevacizumab is the most likely drug to be associated with development of the delayed anastomotic leak in the present patient.

Previous CT scan showed that the circumferential staple line was observed at the anastomotic site (Fig. 4) but was no longer apparent at the time the leak was noted (Fig. 1). Staples might be spontaneously extruded at the anastomotic site during bevacizumab treatment. Some studies demonstrated possible deleterious effects of agents targeting VEGF on healing of colonic anastomoses [23, 24]. Stapled anastomoses are commonly used in rectal cancer surgery and granulation tissue develops around the anastomotic site. There may be ongoing healing and tissue remodeling for years following a low anterior resection in a patient who had received radiation therapy [17]. Bevacizumab may interfere with the ongoing healing process, and an inflamed wound is more at risk of complications from VEGF inhibition at any time during such treatment.
Fig. 4
Fig. 4

Computed tomography scan 3 months before the patient presented with symptoms of a leak shows a circumferential staple line at the anastomotic site

Conclusions

A delayed anastomotic leak with fistula formation after low anterior resection for rectal cancer associated with bevacizumab treatment and preoperative CRT must be considered. Signs or symptoms suggestive of anastomotic complications should be evaluated during bevacizumab treatment, even long after the initial surgery.

Abbreviations

5-FU: 

5-Fluorouracil

CRC: 

Colorectal cancer

CRT: 

Chemo-radiotherapy

CT: 

Computed tomography

Gy: 

Gray

VEGF: 

Vascular endothelial growth factor

Declarations

Acknowledgements

Not applicable.

Funding

This research did not receive any specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Availability of data and materials

Not applicable.

Authors’ contributions

EM wrote the manuscript and participated in the postoperative care. YM supervised the writing of the manuscript and was responsible for the out-patient care. JT, ST, HI, FH, RK, and ST participated in the postoperative care. AKL and TR critically revised the manuscript. All authors have read and approved the final manuscript for submission.

Ethics approval and consent to participate

The institutional ethics committee determined that approval was not necessary for a case report. However, patient anonymity has been preserved and personal information has been protected. Informed consent was obtained from the patient.

Consent for publication

Written consent for the publication of this case report with accompanying images was obtained from the patient.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Authors’ Affiliations

(1)
Department of Surgery, Saitama Medical Center, Jichi Medical University, 1-847 Amanuma-cho, Omiya-ku, Saitamashi Saitamaken, 330-8503, Japan
(2)
Department of Surgery, Jichi Medical University, Tochigi, Japan

References

  1. Kabbinavar FF, Schulz J, McCleod M, Patel T, Hamm JT, Hecht JR, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol. 2005;23(16):3697–705.View ArticleGoogle Scholar
  2. Cohen MH, Gootenberg J, Keegan P, Pazdur R. FDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer. Oncologist. 2007;12(3):356–61.View ArticleGoogle Scholar
  3. Schutz FA, Je Y, Azzi GR, Nguyen PL, Choueiri TK. Bevacizumab increases the risk of arterial ischemia: a large study in cancer patients with a focus on different subgroup outcomes. Ann Oncol. 2011;22(6):1404–12.View ArticleGoogle Scholar
  4. Hapani S, Sher A, Chu D, Wu S. Increased risk of serious hemorrhage with bevacizumab in cancer patients: a meta-analysis. Oncology. 2010;79(1–2):27–38.View ArticleGoogle Scholar
  5. Hapani S, Chu D, Wu S. Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. Lancet Oncol. 2009;10(6):559–68.View ArticleGoogle Scholar
  6. August DA, Serrano D, Poplin EB. Spontaneous delayed colon and rectal anastomotic complications associated with bevacizumab therapy. J Surg Oncol. 2008;97(2):180–5.View ArticleGoogle Scholar
  7. Ley EJ, Vukasin P, Kaiser AM, Ault G, Beart RW Jr. Delayed rectovaginal fistula: a potential complication of bevacizumab (Avastin). Dis Colon Rectum. 2007;50(6):930.View ArticleGoogle Scholar
  8. Bege T, Lelong B, Viret F, Turrini O, Guiramand J, Topart D, et al. Bevacizumab-related surgical site complication despite primary tumor resection in colorectal cancer patients. Ann Surg Oncol. 2009;16(4):856–60.View ArticleGoogle Scholar
  9. Adenis A, Vanseymortier L, Foissey D, Colombel JF. Bevacizumab and postponed suture leakages after surgery for ulcerative colitis and rectal cancer. Gut. 2007;56(5):734.View ArticleGoogle Scholar
  10. Borzomati D, Nappo G, Valeri S, Vincenzi B, Ripetti V, Coppola R. Infusion of bevacizumab increases the risk of intestinal perforation: results on a series of 143 patients consecutively treated. Updat Surg. 2013;65(2):121–4.View ArticleGoogle Scholar
  11. O'Hare T, McDermott R, Hannon R. Late anastomotic breakdown with bevacizumab in colorectal cancers, a case-based review. Ir J Med Sci. 2018;187(2):333–6.View ArticleGoogle Scholar
  12. Kingham TP, Pachter HL. Colonic anastomotic leak: risk factors, diagnosis, and treatment. J Am Coll Surg. 2009;208(2):269–78.View ArticleGoogle Scholar
  13. Qu H, Liu Y, Bi DS. Clinical risk factors for anastomotic leakage after laparoscopic anterior resection for rectal cancer: a systematic review and meta-analysis. Surg Endosc. 2015;29(12):3608–17.View ArticleGoogle Scholar
  14. Kawada K, Sakai Y. Preoperative, intraoperative and postoperative risk factors for anastomotic leakage after laparoscopic low anterior resection with double stapling technique anastomosis. World J Gastroenterol. 2016;22(25):5718–27.View ArticleGoogle Scholar
  15. Shin US, Kim CW, Yu CS, Kim JC. Delayed anastomotic leakage following sphincter-preserving surgery for rectal cancer. Int J Color Dis. 2010;25(9):843–9.View ArticleGoogle Scholar
  16. Lim SB, Yu CS, Kim CW, Yoon YS, Park IJ, Kim JC. Late anastomotic leakage after low anterior resection in rectal cancer patients: clinical characteristics and predisposing factors. Color Dis. 2016;18(4):O135–40.View ArticleGoogle Scholar
  17. Tibbs MK. Wound healing following radiation therapy: a review. Radiother Oncol. 1997;42(2):99–106.View ArticleGoogle Scholar
  18. Botrel TEA, Clark LGO, Paladini L, Clark OAC. Efficacy and safety of bevacizumab plus chemotherapy compared to chemotherapy alone in previously untreated advanced or metastatic colorectal cancer: a systematic review and meta-analysis. BMC Cancer. 2016;16:677.View ArticleGoogle Scholar
  19. Kozloff M, Yood MU, Berlin J, Flynn PJ, Kabbinavar FF, Purdie DM, et al. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study. Oncologist. 2009;14(9):862–70.View ArticleGoogle Scholar
  20. Hatake K, Doi T, Uetake H, Takahashi Y, Ishihara Y, Shirao K. Bevacizumab safety in Japanese patients with colorectal cancer. Jpn J Clin Oncol. 2016;46(3):234–40.View ArticleGoogle Scholar
  21. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med. 2000;343(13):905–14.View ArticleGoogle Scholar
  22. de Man FM, Goey AKL, van Schaik RHN, Mathijssen RHJ, Bins S. Individualization of irinotecan treatment: a review of pharmacokinetics, pharmacodynamics, and pharmacogenetics. Clin Pharmacokinet. 2018;57(10):1229–54.View ArticleGoogle Scholar
  23. Hendriks JM, Hubens G, Wuyts FL, Vermeulen P, Hubens A, Eyskens E. Experimental study of intraperitoneal suramin on the healing of colonic anastomoses. Br J Surg. 1999;86(9):1171–5.View ArticleGoogle Scholar
  24. te Velde EA, Voest EE, van Gorp JM, Verheem A, Hagendoorn J, Gebbink MF, et al. Adverse effects of the antiangiogenic agent angiostatin on the healing of experimental colonic anastomoses. Ann Surg Oncol. 2002;9(3):303–9.View ArticleGoogle Scholar

Copyright

© The Author(s). 2019

Advertisement